Mesa Laboratories, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US59064R1095
USD
77.15
1.09 (1.43%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Mar'19
Net Sales
240.98
216.19
219.08
184.34
133.94
117.69
103.14
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
240.98
216.19
219.08
184.34
133.94
117.69
103.14
Raw Material Cost
108.83
105.43
108.56
96.58
61.87
54.46
49.35
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
11.86
5.70
4.77
3.88
8.02
5.50
0.00
Selling and Distribution Expenses
96.29
86.77
86.71
66.04
48.27
40.05
32.41
Other Expenses
0.77
1.36
1.57
1.19
0.24
0.09
0.35
Total Expenditure (Excl Depreciation)
224.64
211.49
215.76
178.39
120.53
100.86
85.26
Operating Profit (PBDIT) excl Other Income
16.299999999999997
4.699999999999999
3.3000000000000003
5.8999999999999995
13.4
16.8
17.9
Other Income
-1.40
2.12
1.06
2.76
-2.03
1.44
-1.16
Operating Profit (PBDIT)
39.46
38.39
37.52
33.77
28.85
31.14
26.18
Interest
11.86
5.70
4.77
3.88
8.02
5.50
0.00
Exceptional Items
2.89
-276.77
0.00
-1.24
-1.05
-8.90
-8.09
Gross Profit (PBDT)
132.14
110.76
110.52
87.76
72.06
63.23
53.78
Depreciation
24.53
31.57
33.13
25.07
17.47
12.87
9.47
Profit Before Tax
5.96
-275.65
-0.39
3.57
2.30
3.86
8.62
Tax
7.93
-21.40
-1.32
1.70
-0.97
2.08
1.14
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
-1.97
-254.25
0.93
1.87
3.27
1.78
7.48
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
-1.97
-254.25
0.93
1.87
3.27
1.78
7.48
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
-1.97
-254.25
0.93
1.87
3.27
1.78
7.48
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
159.83
145.39
393.48
393.80
406.23
220.01
111.31
Earnings per share (EPS)
-0.36
-47.2
0.17
0.35
0.64
0.41
1.86
Diluted Earnings per share
-0.36
-47.2
0.17
0.35
0.64
0.41
1.86
Operating Profit Margin (Excl OI)
6.78%
2.17%
1.52%
3.23%
10.01%
14.3%
17.33%
Gross Profit Margin
12.65%
-112.9%
14.95%
15.54%
14.76%
14.22%
17.54%
PAT Margin
-0.82%
-117.6%
0.42%
1.01%
2.44%
1.51%
7.26%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 11.47% vs -1.32% in Mar 2024

stock-summary

Consolidate Net Profit

YoY Growth in year ended Mar 2025 is 99.21% vs -28,344.44% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is 12.67% vs -0.55% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 108.77% vs 18.75% in Mar 2024

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Mar 2025 has improved from Mar 2024

Compare Annual Results Of Mesa Laboratories, Inc. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(USD)
Change(%)
Net Sales
240.98
73.24
167.74
229.03%
Other Operating Income
0.00
0.00
0.00
Total Operating income
240.98
73.24
167.74
229.03%
Raw Material Cost
108.83
16.89
91.94
544.35%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0.00
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
11.86
0.00
11.86
Selling and Distribution Expenses
96.29
31.55
64.74
205.20%
Other Expenses
0.77
0.28
0.49
175.00%
Total Expenditure (Excl Depreciation)
224.64
51.28
173.36
338.07%
Operating Profit (PBDIT) excl Other Income
16.34
21.96
-5.62
-25.59%
Other Income
-1.40
2.31
-3.71
-160.61%
Operating Profit (PBDIT)
39.46
25.09
14.37
57.27%
Interest
11.86
0.00
11.86
Exceptional Items
2.89
0.00
2.89
Gross Profit (PBDT)
132.14
56.35
75.79
134.50%
Depreciation
24.53
0.82
23.71
2,891.46%
Profit Before Tax
5.96
24.28
-18.32
-75.45%
Tax
7.93
5.04
2.89
57.34%
Provisions and contingencies
0
0
0.00
Profit After Tax
-1.97
19.23
-21.20
-110.24%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
-1.97
19.23
-21.20
-110.24%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
-1.97
19.23
-21.20
-110.24%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
159.83
86.82
73.01
84.09%
Earnings per share (EPS)
-0.36
1.50
-1.86
-124.00%
Diluted Earnings per share
-0.36
1.50
-1.86
-124.00%
Operating Profit Margin (Excl OI)
6.78%
29.99%
0.00
-23.21%
Gross Profit Margin
12.65%
34.26%
0.00
-21.61%
PAT Margin
-0.82%
26.26%
0.00
-27.08%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 24.10 Million
in Mar 2025

Figures in Million
stock-summary

YoY Growth in year ended Mar 2025 is 11.47% vs -1.32% in Mar 2024

Annual - Consolidate Net Profit
Consolidate Net Profit -0.20 Million
in Mar 2025

Figures in Million
stock-summary

YoY Growth in year ended Mar 2025 is 99.21% vs -28,344.44% in Mar 2024

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 4.09 Million
in Mar 2025

Figures in Million
stock-summary

YoY Growth in year ended Mar 2025 is 12.67% vs -0.55% in Mar 2024

Annual - Interest
Interest 1.19 Million
in Mar 2025

Figures in Million
stock-summary

YoY Growth in year ended Mar 2025 is 108.77% vs 18.75% in Mar 2024

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 6.78%
in Mar 2025

Figures in %
stock-summary

YoY Growth in year ended Mar 2025 has improved from Mar 2024